Meeting
2023 ASCO Annual Meeting
Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.
Authors
Thierry Landre
Hôpitaux-Universitaires-Paris-Seine-St-Denis, AP-HP, Paris, France
Thierry Landre , Abdoulaye Karaboue , Zachary S Buchwald , Pasquale Innominato , David C Qian , Jean-baptiste ASSIE , Christos Chouaid , Francis Levi , Boris Duchemann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immunobiology
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2562)
DOI
10.1200/JCO.2023.41.16_suppl.2562
Abstract #
2562
Poster Bd #
404
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2020 ASCO Virtual Scientific Program
Comparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis.
First Author: Ranjan Pathak
Poster
2022 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).
First Author: Charlee Nardin
Poster
2020 ASCO Virtual Scientific Program
Is there a benefit of immune checkpoint inhibitors for patients over 75 years of age with advanced cancer in first and second line setting: A meta-analysis.
First Author: Thierry Landre